Stay updated on Trametinib and Pembrolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Trametinib and Pembrolizumab in NSCLC Clinical Trial page.

Latest updates to the Trametinib and Pembrolizumab in NSCLC Clinical Trial page
- Check2 days agoChange DetectedThe page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed. Notably, the information regarding the modernization of ClinicalTrials.gov data ingest scheduled for July 2025 has been deleted.SummaryDifference0.8%
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.6%
- Check23 days agoNo Change Detected
- Check31 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check38 days agoChange DetectedThe web page has been updated to reflect a modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
- Check66 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check81 days agoChange DetectedThe webpage has been updated to include new information about various stages of lung cancer and clinical trial identifiers, while significant details regarding the trial's objectives and treatment protocols have been removed.SummaryDifference68%
Stay in the know with updates to Trametinib and Pembrolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Trametinib and Pembrolizumab in NSCLC Clinical Trial page.